FDA Schedule

Definition

The DEA scheduling system (formally established under the Controlled Substances Act of 1970) classifies drugs and chemicals into five schedules based on their medical utility, potential for abuse, and safety profile. Schedule I substances have no currently accepted medical use and high abuse potential (examples: heroin, LSD). Schedule II substances have accepted medical uses but high abuse potential (examples: morphine, amphetamine). Schedule III through V substances have progressively lower abuse potential and are more widely available. Research peptides such as BPC-157, TB-500, and GHK-Cu are not currently scheduled under the Controlled Substances Act at the federal level.

Research Context

Understanding the federal scheduling status of research compounds is an important due diligence step for researchers and institutions procuring these materials. The scheduling status of a compound determines what regulatory controls apply to its possession, use, and distribution. Peptide research compounds that are not scheduled substances are subject to general commerce regulations rather than DEA controlled substance requirements. However, researchers should verify current scheduling status for each compound they procure, as the regulatory landscape can change, and some state laws impose additional controls beyond federal scheduling.